 MALVERN, Pa., June 08, 2021 GLOBE NEWSWIRE -- Baudax Bio, Inc. NASDAQ:BXRX, a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that ANJESO meloxicam injection has achieved approvals at over 100 formularies across the U.S. in under one year of commercialization. ANJESOs presence on formularies is expected to drive usage through regular availability at both hospitals and ambulatory care centers covered by these formularies. 